Patent · US Active

Dosage regimen for administering a CD19XCD3 bispecific antibody

US8840888B2 · kind B2 · utility

17Cited by

1References

34Claims

0Family size

Assignee

Micromet AG · DE

Inventors

Dirk Nagorsen · Munich, DE
Peter Kufer · Munich, DE
Gerhard Zugmaier · Munich, DE
Patrick Baeuerle · Gauting, DE

Key dates

Filing date	Oct 27, 2010
Grant date	Sep 23, 2014
Priority date	—
Expiry date	Oct 27, 2030

Classification

Technology area (CPC G)Physics
CPC primaryG01N2800/52
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided herein is a method for assessing the risk of potential adverse effects for a human patient mediated by the administration of a CD19.times.CD3 bispecific antibody to said patient comprising determining the ratio of B cells to T cells of said patient, wherein a ratio of about 1:5 or lower is indicative for a risk of potential adverse effects for said patient.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.